Poster Ozen Ayranci Osmanbasoglu

Advantages:

To assess the effect of intravitreal (IV) ranibizumab therapy on retinal nerve fiber layer (RNFL) thickness.

Methods:

Fourteen eyes of 11 treatment naive patients with neovascular age related macular degeneration treated with ranibizumab were included. Patients were followed up by monthly examinations and IV ranibizumab injections were done as on needed basis. RNFL thickness s was measured by time domain optical coherence tomography at each examination. Intraocular pressure (IOP) was measured before and 1 hour after intravitreal injections. Central-superior-temporal-nasal-inferior RNFL thicknesses and IOP change were analysed with repeated measures ANOVA

Effectiveness / Safety:

The mean age of patients was 76.5 ±10.5 years. The mean follow up time was 5.3 ±1.1 months and mean number of injections was 3.3 ±0.9. Baseline RNFL thicknesses were 96.8 ±8.5 µm in the central, 117.2 ±16.2 µm in the superior, 71.2 ±14.4 µm in the temporal, 76.5 ±16.9 µm in the nasal and 119.7 ±23.8 µm in the inferior quadrant. During the follow up significant RNFL thinning was noted in the central and superior quadrant, whereas the IOP change was insignificant and none of the patients experienced an IOP spike of 5 mmHg or more. This result can be attributed to the direct toxic effect of the drug as no significant IOP change due to the injections was observed.